Objective:
The aim of this study was to compare images from Tc-99m MDP bone scan
(BS) and Ga-68 PSMA PET/CT of patients with prostate cancer in terms of bone metastases.
Methods:
Overall, 34 patients exhibited a mean age of 66 ± 9.5 (50-88) years, mean PSA of 51 ±
159ng/ml (0-912), and mean Gleason score of 8 (6-9). BS and Ga-68 PSMA PET/CT were applied
to 34 patients within 30 days, and the results were evaluated, retrospectively. In both tests, radiopharmaceutical
uptake in bones were compared.
Results:
In 7 patients (20.5%), uptake was not significant on BS and Ga-68 PSMA PET / CT images,
which is related to metastasis. In 14 (41%) patients, bone metastases were observed in both
examinations. However, more metastatic lesions were observed in the Ga-68 PSMA PET/CT of 3
patients and in the bone scintigraphy of 2 patients. PSMA expression was not observed on Ga-68
PSMA PET / CT in 13 (38%) patients with increased activity in bone scintigraphy. Two (6%) of
these patients were thought to be metastatic, 2 (6%) were suspicious for metastasis, and 9 (26%)
had no metastasis. When a lesion-based evaluation was performed, a total of 480 activities were
evaluated: increased activity uptake was found in 305 BS, and 427 PSMA expression activity was
detected. Furthermore, 435 of these activities were evaluated as metastatic.
Conclusion:
Ga-68 PSMA PET/CT provides an additional contribution to the BS evaluation of activity
areas because of the presence of PSMA expression and anatomical lesions. In 6% of the patients,
activity on BS and metastatic appearance in CT images were observed and the presence of
lesions in the absence of PSMA was determined. This suggests that bone metastases without
PSMA expression may also be present.
The Role of Ga-68-PSMA PET/CT in the Initial Staging of Prostate Cancer – A Single Center 4 Year Experience
